Dana Farber Best of ASH Conference 1/12/13 Waltham, Ma.
I attended today and brentuximab was discussed at length and favorably. No question that it will start to play a large role in the Rx of T cell lymphoma. They also thought it very likely would find its way into front line Rx for HD patients with poor prognostic factors and/or bulky disease. However, they didn't think it was likely to be used in the majority of front line patients because of $$ and mild-moderate toxicity issues.